Genome-wide cell-free DNA fragmentation in patients with cancer

Stephen Cristiano(Johns Hopkins University), Alessandro Leal(Johns Hopkins University), Jillian Phallen(Johns Hopkins University), Jacob Fiksel(Sidney Kimmel Comprehensive Cancer Center), Vilmos Adleff(Johns Hopkins University), Daniel C. Bruhm(Johns Hopkins University), Sarah Østrup Jensen(Aarhus University Hospital), Jamie E. Medina(Sidney Kimmel Comprehensive Cancer Center), Carolyn Hruban(Johns Hopkins University), James R. White(Johns Hopkins University), Doreen N. Palsgrove(Johns Hopkins University), Noushin Niknafs(Sidney Kimmel Comprehensive Cancer Center), Valsamo Anagnostou(Johns Hopkins University), Patrick M. Forde(Sidney Kimmel Comprehensive Cancer Center), Jarushka Naidoo(Sidney Kimmel Comprehensive Cancer Center), Kristen A. Marrone(Johns Hopkins University), Julie R. Brahmer(Johns Hopkins University), Brian Woodward(University of California, San Diego), Hatim Husain(University of California, San Diego), Karlijn L. van Rooijen(University Medical Center Utrecht), Mai‐Britt W. Ørntoft(Aarhus University Hospital), Anders Husted Madsen(Regionshospitalet Herning), Cornelis J.�H. van de Velde(Leiden University Medical Center), Marcel Verheij(The Netherlands Cancer Institute), Annemieke Cats(The Netherlands Cancer Institute), Cornelis J. A. Punt(Academic Medical Center), Geraldine R. Vink(Utrecht University), Nicole C.T. van Grieken(Amsterdam UMC Location VUmc), Miriam Koopman(University Medical Center Utrecht), Remond J.A. Fijneman(The Netherlands Cancer Institute), Julia S. Johansen(Gentofte Hospital), Hans Jørgen Nielsen(Hvidovre Hospital), Gerrit A. Meijer(Oncode Institute), Claus L. Andersen(Aarhus University Hospital), Robert B. Scharpf(Johns Hopkins University), Victor E. Velculescu(Johns Hopkins University)
Nature
May 29, 2019
Cited by 1,451Open Access
Full Text

Abstract

Cell-free DNA in the blood provides a non-invasive diagnostic avenue for patients with cancer1. However, characteristics of the origins and molecular features of cell-free DNA are poorly understood. Here we developed an approach to evaluate fragmentation patterns of cell-free DNA across the genome, and found that profiles of healthy individuals reflected nucleosomal patterns of white blood cells, whereas patients with cancer had altered fragmentation profiles. We used this method to analyse the fragmentation profiles of 236 patients with breast, colorectal, lung, ovarian, pancreatic, gastric or bile duct cancer and 245 healthy individuals. A machine learning model that incorporated genome-wide fragmentation features had sensitivities of detection ranging from 57% to more than 99% among the seven cancer types at 98% specificity, with an overall area under the curve value of 0.94. Fragmentation profiles could be used to identify the tissue of origin of the cancers to a limited number of sites in 75% of cases. Combining our approach with mutation-based cell-free DNA analyses detected 91% of patients with cancer. The results of these analyses highlight important properties of cell-free DNA and provide a proof-of-principle approach for the screening, early detection and monitoring of human cancer. Analyses of fragmentation patterns of cell-free DNA in the blood of patients with cancer and healthy individuals using a machine learning algorithm provide a proof-of principle approach for the early detection and screening of human cancer.


Related Papers

No related papers found

Powered by citation graph analysis